Literature DB >> 19596665

Factors that affect the duration of the interval between the completion of palliative chemotherapy and death.

Kenji Hashimoto1, Kan Yonemori, Noriyuki Katsumata, Marika Hotchi, Tsutomu Kouno, Chikako Shimizu, Kenji Tamura, Masashi Ando, Masahiro Takeuchi, Yasuhiro Fujiwara.   

Abstract

BACKGROUND: The purpose of this study was to identify factors that affect the duration of the interval between the completion of palliative chemotherapy and death.
METHODS: We retrospectively analyzed 255 cases in which patients had received palliative chemotherapy in the medical oncology division and died during the period 2002-2006. Univariate and multivariate analyses were performed to identify factors that affected the duration of the interval between the completion of chemotherapy and death.
RESULTS: There were 133 cases of breast cancer, 77 cases of gynecological cancer, 24 cases of primary unknown cancer, and 21 cases of other cancers. The median interval between the completion of chemotherapy and death was 100 days (range, 5-1,206 days). Thirty-two patients (12.6%) died within 30 days, and 82 patients (32.3%) died within 60 days. Fifty-eight (22.7%) patients were symptomatic when chemotherapy was started, and 205 patients (80.4%) were provided information about palliative care units at the start of chemotherapy. The factors associated with a short interval between the completion of chemotherapy and death (< or = 90 days) according to the univariate analysis were male sex, young age (< or = 45 years), attending physician, poor Eastern Cooperative Oncology Group performance status score (3 or 4), obvious symptoms, and not having been given information about palliative care units. The results of the multivariate analysis indicated that young patients (< or = 45 years) who had not been referred to a palliative care unit and who had symptoms survived for a significantly shorter time interval.
CONCLUSION: Young patients who were symptomatic tended to choose chemotherapy instead of entering a palliative care unit until the very near-the-end-of-life stage.

Entities:  

Mesh:

Year:  2009        PMID: 19596665     DOI: 10.1634/theoncologist.2008-0257

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  14 in total

1.  Factors associated with discharge disposition on an acute palliative care unit.

Authors:  David Hausner; Nanor Kevork; Ashley Pope; Breffni Hannon; John Bryson; Jenny Lau; Gary Rodin; Lisa W Le; Camilla Zimmermann
Journal:  Support Care Cancer       Date:  2018-05-30       Impact factor: 3.603

2.  A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer.

Authors:  Kenji Hashimoto; Kan Yonemori; Chikako Shimizu; Akihiro Hirakawa; Harukaze Yamamoto; Makiko Ono; Taizo Hirata; Tsutomu Kouno; Kenji Tamura; Noriyuki Katsumata; Masashi Ando; Yasuhiro Fujiwara
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

3.  Can oncologists predict survival for patients with progressive disease after standard chemotherapies?

Authors:  T K Taniyama; K Hashimoto; N Katsumata; A Hirakawa; K Yonemori; M Yunokawa; C Shimizu; K Tamura; M Ando; Y Fujiwara
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

4.  Chemotherapy at the end of life: up until when?

Authors:  Jaime Sanz Ortiz
Journal:  Clin Transl Oncol       Date:  2012-07-07       Impact factor: 3.405

5.  What determines the timing of discussions on forgoing anticancer treatment? A national survey of medical oncologists.

Authors:  Masanori Mori; Chikako Shimizu; Asao Ogawa; Takuji Okusaka; Saran Yoshida; Tatsuya Morita
Journal:  Support Care Cancer       Date:  2018-08-25       Impact factor: 3.603

6.  The importance of good death components among cancer patients, the general population, oncologists, and oncology nurses in Japan: patients prefer "fighting against cancer".

Authors:  Mitsunori Miyashita; Sachiko Kawakami; Daiki Kato; Hideomi Yamashita; Hiroshi Igaki; Kimiko Nakano; Yujiro Kuroda; Keiichi Nakagawa
Journal:  Support Care Cancer       Date:  2014-07-05       Impact factor: 3.603

7.  Perspectives of Medical Specialists on Sharing Decisions in Cancer Care: A Qualitative Study Concerning Chemotherapy Decisions With Patients With Recurrent Glioblastoma.

Authors:  Janine C De Snoo-Trimp; Linda Brom; H Roeline W Pasman; Bregje D Onwuteaka-Philipsen; Guy A M Widdershoven
Journal:  Oncologist       Date:  2015-08-05

8.  The realities and associated factors of palliative chemotherapy near the end of life in the patients enrolled in palliative care unit.

Authors:  Daeun Jung; Sunjin Hwang; Hyun Jung You; Jungkwon Lee
Journal:  Korean J Fam Med       Date:  2012-01-31

9.  Time from last chemotherapy to death and its correlation with the end of life care in a referral hospital.

Authors:  Syed Mustafa Karim; Jamal Zekri; Ehab Abdelghany; Reyad Dada; Husna Munsoor; Imran Ahmad
Journal:  Indian J Med Paediatr Oncol       Date:  2015 Jan-Mar

10.  Use of chemotherapy at the end of life in Turkey.

Authors:  Sema Sezgin Goksu; Seyda Gunduz; Dilek Unal; Mukremin Uysal; Deniz Arslan; Ali M Tatlı; Hakan Bozcuk; Mustafa Ozdogan; Hasan S Coskun
Journal:  BMC Palliat Care       Date:  2014-11-19       Impact factor: 3.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.